KNC Laboratories Co.,Ltd.

KNC Laboratories Co.,Ltd.

6.70
EUR
+0.16
(+2.45%)
Nov 13Next Earn
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
624.94
794.67
1,039.52
814.86
820.51
777.46
957.23
1,118.79
1,186.46
1,058.45
1,175.21
- -
Basic EPS, GAAP
53
80.72
148.35
121.29
67.02
51.54
82.78
200.06
193.5
95.42
99.02
- -
Free Cash Flow per Basic Share
-68.44
125.71
225.73
-89.16
-246.29
56.05
-31.94
112
110.18
-235.15
-46.98
- -
Dividend per Share
2.71
10
14.82
24.92
24.93
24.96
24.95
35.22
32.97
30.97
32.97
- -
Book Value per Share
485.52
541.93
1,131.65
1,224.71
1,268.85
1,304.18
1,359.28
1,523.41
1,695.35
1,748.68
1,818.88
- -
Tangible Book Value per Share
457.57
536.9
1,127.9
1,214.54
1,258.07
1,296.36
1,353.41
1,515.17
1,688.43
1,742.02
1,811.01
- -
Basic Weighted Avg Shares
7
6
6
8
8
8
8
8
8
8
8
8
Sales/Revenue/Turnover
4,612
4,768
6,313
6,291
6,348
6,029
7,441
8,628
9,155
8,179
9,094
- -
Operating Margin (%)
6.45
14.87
19.36
19.72
9.05
10.54
14.71
25.08
22.74
9.44
11.27
- -
Depreciation Expense
878
836
782
755
803
940
929
919
922
879
1,233
- -
Net Income, GAAP
391
484
901
936
518
400
643
1,543
1,493
737
766
- -
Effective Tax Rate (%)
- -
32.99
26.6
27.73
26.45
31.79
29.81
28.98
28.67
20.55
25.31
- -
Profit Margin (%)
8.48
10.16
14.27
14.88
8.17
6.63
8.65
17.88
16.31
9.01
8.43
- -
Working Capital
610
890
4,151
2,442
2,619
3,850
4,301
4,731
5,590
5,207
5,085
- -
LT Debt
2,937
2,257
978
200
968
1,083
1,037
597
1,312
2,267
2,494
- -
Total Equity
3,748
4,184
8,737
9,455
9,827
10,121
10,575
11,745
13,087
13,520
14,081
- -
Return on Invested Capital (%)
- -
6.16
9.39
8.08
3.82
3.74
6.29
11.56
9.78
3.67
4.41
- -
Return on Capital (%)
- -
6.57
9.91
8.81
4.83
3.57
5.46
12.14
10.58
4.75
4.62
- -
Return on Common Equity (%)
- -
12.21
13.95
10.29
5.38
4.01
6.22
13.82
12.03
5.54
5.55
- -

Capital Structure

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
ST Debt
902
1,103
- -
LT Borrowings
2,278
2,494
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
8
8
8
Market Capitalization
- -
- -
9,187

Working Capital

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
Total Current Assets
7,191
7,811
- -
Cash, Cash Equivalents & STI
2,241
2,173
- -
Accounts Receivable, Net
1,071
1,735
- -
Inventories
3,344
3,291
- -
Total Current Liabilities
2,781
2,726
- -
Payables & Accruals
- -
- -
- -
ST Debt
902
1,103
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
17%
6.88%
4.14%
Free Cash Flow
-126.41%
-200.06%
-79.99%
Net Income, GAAP
19.71%
30.17%
3.92%
Sales/Revenue/Turnover
7.73%
9.2%
11.18%
Total Cash Common Dividend
39.9%
6.93%
6.63%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
8,179
2026
- -
- -
- -
- -
9,094
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
95.42
2026
- -
- -
- -
- -
99.02
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
30.97
2026
- -
- -
- -
- -
32.97
2027
- -
- -
- -
- -
- -

Company Description

CEO
Takuya Maoka
Full Time Employees
340
Sector
Commercial services
Industry
Miscellaneous commercial services
Address
7-1-19 Minatojimaminamimachi Kobe HY Japan 650-0047
IPO Date
Mar 15, 2018
Business
KNC Laboratories Co., Ltd. KNC Laboratories Co., Ltd. (6568.T) engages in the research, development, and production of organic chemicals, providing contract manufacturing organization (CMO) and contract research organization (CRO) services across the pharmaceutical, electronic-chemical, agrochemical, energy, and environmental industries. The company offers core products and services including active pharmaceutical ingredients (APIs), protein and peptide synthesis, nucleic acid synthesis, bio-conversion processes, microbial culture, separation and purification technologies, scale-up and mass production of organic compounds, research reagents, original equipment manufacturing (OEM), full-time equivalent (FTE) research, sample production, period-defined custom research, and commercial production solutions. These capabilities support clients from early-stage research through to large-scale manufacturing, with specialized expertise in organic synthetic chemistry and biotechnology. Founded on January 22, 1985, and headquartered on Port Island in Chuo-ku, Kobe, Japan, KNC Laboratories operates primarily in Japan with facilities including the Kobe Plant, Kobe Laboratory, Izumo Plant, and historical sites such as the Iwaoka Plant and Ichikawa Laboratory. The company targets pharmaceutical companies, chemical manufacturers, and research institutions, delivering tailored solutions for drug development, reagent supply, and industrial applications. In recent developments, KNC Laboratories transitioned from the Tokyo Stock Exchange's Mothers market to the Growth market in April 2022, enhancing its visibility and access to capital markets. The company relocated its head office and Kobe Laboratory to Port Island, Chuo-ku, Kobe in December 2019, optimizing operations in a high-tech hub. As of April 1, 2025, it employs 346 staff and maintains a capital base of ¥1,995,106,630, with no major acquisitions, partnerships, or new product launches reported in the last 1-2 years.